TERMS OF REFERENCE (TOR)
FOR TWO TECHNICAL ADVISORS TO SUPPORT THE PROJECT STEERING COMMITTEE IN THE IMPLEMENTATION OF A SITUATION ANALYSIS FOR THE PHARMACEUTICAL PRICING POLICY FOR NAMIBIA

1. Background

A Pharmaceutical pricing policy is a set of written principles or requirements for managing the prices of pharmaceutical products, agreed or adopted by a public institution, a group of purchasing organizations or individual health services. The importance of attaining affordable access to pharmaceutical products in the global efforts towards universal health coverage has long been recognized. Most recently, the United Nations Sustainable Development Goals (SDGs) has set SDG Target 3.8 as “financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all”. By extension, achieving this SDG is the responsibility of all levels of governments of Member States and the global community.

Currently, there are various options of policy interventions that could be applied for setting, managing or influencing prices of pharmaceutical products that countries can choose from based on their local contexts. Therefore, countries are expected to choose the most suitable pricing intervention(s) that fits its local context before commencing the development of national pricing policy. The Ministry of Health and Social Services (MoHSS) through financial and technical support from the United Nations Development Programme (UNDP) would, therefore, like to recruit 2Xtechnical advisors to conduct a situation analysis on pricing strategies and medicines prices in the private and public sector, and make evidence based recommendations on the most suitable pricing strategy(s) for Namibia.

The two advisors will work with a local consultant in determining the need for a new medicines pricing policy for Namibia: and provide advisory support to the Project Steering Committee.

2. General Objective

To support the Ministry of Health in assessing the need for a medicine pricing policy and if required, develop a roadmap for the development of the medicine pricing policy

3. Specific Objectives

• To support the MOHSS to provide high quality technical oversight of the work of the consultants
• To provide the MOHSS with regular updates on the outputs of the consultants activities
• To conduct with the MoHSS a stakeholder consultation on the proposal for the need for a new medicines pricing policy

4. Position Title

International Technical Advisor

5. Scope of Work

• Kick-off/Inception Meeting with MOHSS to confirm the ToR of the Project Steering Committee
• Review the workplan of the consultant/s and provide guidance to the MoHSS throughout the process
• Discuss the updates from the consultant/s with the MoHSS and provide recommendations on how to maximize the utility of the work of the consultant/s/s
• Review the deliverables of the consultant/s and provide advice to the MoHSS to inform next steps
• Based on the results of the consultants’ activities, advice the MOHSS on the need for a new medicines pricing policy.
• If the policy is required, provide technical inputs on the roadmap to develop the policy, including through consultation with internal and external stakeholders

6. Deliverables
• Guidance to the MoHSS before, during and after the contracting of the consultant/s
• Oversight and supervision of technical deliverables
• High quality situational analysis report on the need for medicine pricing policy in Namibia
• Stakeholder engagements for internal and external stakeholders
• Support the review and validation of the pricing policy for Namibia

7. Deliverables and Payment Milestones and Percentages

<table>
<thead>
<tr>
<th>Deliverables/outputs</th>
<th>Target Due Dates</th>
<th>Review and Approvals Required</th>
<th>Payment Milestones/Percentages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deliverable 1:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development and Review Situational Analysis</td>
<td>20 March 2022</td>
<td>The consultant will seek final approval from UNDP and MoHSS</td>
<td>10%</td>
</tr>
<tr>
<td>Deliverable 2:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review of the pricing policy strategy</td>
<td>15 May 2022</td>
<td>The consultant will seek final approval from UNDP and MoHSS</td>
<td>30%</td>
</tr>
<tr>
<td>Deliverable 3:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stakeholder engagement and final report review of final report</td>
<td>30 June 2022</td>
<td>The consultant will seek final approval from UNDP and MoHSS</td>
<td>60%</td>
</tr>
</tbody>
</table>

8. Education
• Essential: Master in Public Health/ Master in Sciences/ Master in Health Economics/Master of Business Administration or similar degree in the field of Medical or Pharmaceutical Sciences
• Desirable: PhD/DrPH, knowledge in Health Systems Strengthening and Pharmaceutical Policy Development

9. Experience
• At least 10 years of experience in the field of Pharmaceutical Policy Development, of which ideally at least 5 years working in the pharmaceutical sector in the SADC and/ or African Region.
10. Desirable Experience
   • Extensive knowledge and experience in Health Systems Strengthening and the development and implementation of policies, strategies and plans. Extensive knowledge of Pharmaceutical Systems in the WHO African Region will be an added advantage.

11. Competency requirements
   • Technical expertise and experience in performing analysis, interpretation of data to inform pharmaceutical pricing policies;
   • Proven track record of delivering projects of similar scope and complexity within constrained timeframes; and
   • Demonstrated ability to work in partnership with the Ministries of Health and other health related and relevant organizations/ institutions.

12. Duration and Work Practices
12 working days over a period of 7 months.

Meetings will be virtual. The MoHSS will provide a secretariat for the project steering committee who will circulate documents in advance of meetings, take minutes during the meetings and prepare a draft report for review by the technical advisors.